Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States

References

• Coyne KS, Sexton CC, Vats V, et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–1087.
   PubMed Web of Science ®Google Scholar
• Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. Linthicum (MD): American Urological Association; 2019.
   Google Scholar
• Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7(4):455–463.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Kopp ZS, et al. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011;108(9):1459–1471.
   PubMed Web of Science ®Google Scholar
• Johnston KM, Walker DR, Lakzadeh P. Characterizing the health-related quality of life burden of overactive bladder using disease-specific patient-reported outcome measures: a systematic literature review. Adv Ther. 2019;36(3):548–562.
   PubMed Web of Science ®Google Scholar
• Milsom I, Kaplan SA, Coyne KS, et al. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology. 2012;80(1):90–96.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Wein A, Nicholson S, et al. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20(2):130–140.
   PubMed Web of Science ®Google Scholar
• Yehoshua A, Chancellor M, Vasavada S, et al. Health resource utilization and cost for patients with incontinent overactive bladder treated with anticholinergics. J Manag Care Spec Pharm. 2016;22(4):406–413.
   PubMedGoogle Scholar
• Szabo SM, Gooch K, Schermer C, et al. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study. BMJ Open. 2019;9(5):e026391.
   PubMed Web of Science ®Google Scholar
• Stefanacci RG, Yeaw J, Shah D, et al. Overactive bladder health care burden in the US long-term care setting: a retrospective cohort study. J Clin Pathways. 2021;7(4):34–42.
   Google Scholar
• Kelleher C, Hakimi Z, Zur R, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324–333.
   PubMed Web of Science ®Google Scholar
• Mitcheson HD, Samanta S, Muldowney K, et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. Eur Urol. 2019;75(2):274–282.
   PubMed Web of Science ®Google Scholar
• Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–1395.
   PubMed Web of Science ®Google Scholar
• Staskin D, Frankel J, Varano S, et al. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316–324.
   PubMed Web of Science ®Google Scholar
• Urovant Sciences. GEMTESA® (vibegron). Irvine (CA); 2020.
   Google Scholar
• Frankel J, Varano S, Staskin D, et al. Vibegron improves quality-of-life measures in patients with overactive bladder: patient-reported outcomes from the EMPOWUR study. Int J Clin Pract. 2021;75(5):e13937.
   PubMed Web of Science ®Google Scholar
• US Census Bureau Population Division. Current population survey, annual social and economic supplement. [updated 2019 March; cited 2020 Apr 6]. Available from: https://data.census.gov/mdat/#/.
   Google Scholar
• Coyne KS, Sexton CC, Bell JA, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013;32(3):230–237.
   PubMed Web of Science ®Google Scholar
• Arias E, Xu J. National vital statistics report: United States life tables, 2017. Hyattsville (MD): National Center for Health Statistics; 2019.
   Google Scholar
• Wielage RC, Perk S, Campbell NL, et al. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives. J Med Econ. 2016;19(12):1135–1143.
   PubMed Web of Science ®Google Scholar
• Anger JT, Goldman HB, Luo X, et al. Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States. Neurourol Urodyn. 2018;37(1):213–222.
   PubMed Web of Science ®Google Scholar
• Linder BJ, Gebhart JB, Elliott DS, et al. National patterns of filled prescriptions and third-line treatment utilization for privately insured women with overactive bladder. Female Pelvic Med Reconstr Surg. 2021;27(2):e261–e266.
   PubMed Web of Science ®Google Scholar
• Astellas Pharma US Inc. MYRBETRIQ^® (mirabegron extended-release tablets). Northbrook (IL); 2018.
   Google Scholar
• Desroziers K, Aballéa S, Maman K, et al. Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder. Health Qual Life Outcomes. 2013;11(1):200.
   PubMedGoogle Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. ICER’s reference case for economic evaluations: principles and rationale. [updated 2020 Jan 31].
   Google Scholar
• US Department of Labor. CPI Inflation Calculator—Medical Care Component: medical care in U.S. city average, all urban consumers, seasonally adjusted. 2020 [cited 2020 June 22]. Available from: https://beta.bls.gov/dataViewer/view/timeseries/CUSR0000SAM
   Google Scholar
• Bridges JF, Onukwugha E, Mullins CD. Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US. Pharmacoeconomics. 2010;28(3):175–184.
   PubMed Web of Science ®Google Scholar
• Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165–178.
   PubMedGoogle Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797.
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. 2020–2023 Value assessment framework. 2020. [cited 2021 April 21]. Available from: https://icer.org/our-approach/methods-process/value-assessment-framework/.
   Google Scholar
• Roberts M, Russell LB, Paltiel AD, et al. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. Value Health. 2012;15(6):804–811.
   PubMed Web of Science ®Google Scholar
• Shepherd JP, Carter-Brooks CM, Chermanksy C. A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder. Int Urogynecol J. 2018;29(8):1213–1219.
   PubMed Web of Science ®Google Scholar
• Murray B, Hessami SH, Gultyaev D, et al. Cost-effectiveness of overactive bladder treatments: from the US payer perspective. J Comp Eff Res. 2019;8(1):61–71.
   PubMed Web of Science ®Google Scholar
• Harvie HS, Amundsen CL, Neuwahl SJ, et al. Cost-effectiveness of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: Results of the ROSETTA randomized trial. J Urol. 2020;203(5):969–977.
   PubMed Web of Science ®Google Scholar